For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.

What is the 340B Program? This program, administered by the Health Resources and Services Administration (HRSA), allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Hospitals use 340B savings to provide, for example, free care for uninsured patients, offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs. According to HRSA, enrolled hospitals and other covered entities can achieve average savings of 25% to 50% in pharmaceutical purchases.

Which organizations are eligible? Several types of hospitals are eligible to participate in the 340B program including critical access hospitals (CAHs), sole community hospitals (SCHs), rural referral centers (RRCs), public and private nonprofit disproportionate share hospitals (DSHs) that serve high numbers of low-income and indigent populations, and free-standing cancer and children’s hospitals. Several types of federal grantee organizations such as community health centers also are eligible to participate in the program.

What are some challenges to the program? Despite rigorous oversight from HRSA and the program’s proven record of expanding access to care for Americans nationwide, critics continue to push to diminish the scope of the program and the benefits it affords eligible providers and their patients.
 

340B Resources

Member Resources

Join the 340B Alliance Banner

The AHA Advocacy Alliance for the 340B program focuses on promoting the value that the 340B program provides to hospitals, patients and communities, as well as preventing attempts to scale back this program. Join the alliance for access to email communications, conference calls and special briefings. Join the Alliance.


Through email communications like alliance emails, action alerts and special messages, the 340B Alliance keeps hospitals informed of the latest news and developments on the program, as well as actions hospital leaders can take to support the program. Learn More

Image of medicine in pharmacy

Latest 340B Content

340B Advocacy Alliance Bulletin
The AHA today issued a Regulatory Advisory that includes a detailed summary of the Health Resources and Services Administration announcement on the new 340B Rebate Model Program
Fact Sheets
The 340B Drug Pricing Program was established by Congress to ensure that hospitals serving low-income, rural and medically underserved communities are able to stretch limited federal resources and use their savings to maintain, improve and expand access to care.
Advisories
On Aug. 3, the Health Resources and Services Administration (HRSA) issued a Federal Register notice announcing a new 340B Rebate Model Program.
Webinar Recordings

The AHA hosted a webinar for members on Aug. 5, during which AHA staff discussed the recently released CY 2027 Physician Fee Schedule proposed rule. The proposed rule includes updates to physician fee schedule rates and other aspects of physician payment. It also contains proposals related to the Medicare Prescription Drug Inflation Rebate Program 340B Data Repository, Medicare Shared Savings Program, Quality Payment Program and Ambulatory Specialty Model. During the webinar, AHA staff reviewed these and other proposed policies included in the rule.

Action Alerts
The Centers for Medicare & Medicaid Services (CMS) is seeking comments on its hospital outpatient prospective payment system proposed rule for calendar year 2027. Comments are due to CMS by Aug. 31.
Headline
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act), a bill aimed at providing statutory clarity for the 340B Drug Pricing Program while establishing new transparency, reporting and program integrity requirements. The bill was introduced by Sens. Jerry Moran, R-Kan.; Tammy Baldwin, D-Wis.; Shelley Moore Capito, R-W.Va.; Tim Kaine, D-Va.; John Boozman, R-Ark.; and John Hickenlooper, D-Colo.
340B Advocacy Alliance Bulletin
A bipartisan group of senators today introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act),
Headline
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers to use rebates rather than upfront discounts to effectuate the 340B ceiling price for certain drugs purchased by 340B covered entities. 
340B Advocacy Alliance Bulletin
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers to use rebates rather than upfront discounts to effectuate the 340B ceiling price for certain drugs purchased by 340B covered entities.
Press Releases
The AHA is deeply concerned that HHS has chosen to move forward with a 340B Rebate Model Program despite the overwhelming evidence that it will impose massive new administrative and financial burdens on hospitals that serve America's most vulnerable patients.